Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1
Abstract Lung adenocarcinoma is the major subtype of lung cancer, accounting for approximately 40% of lung cancers. During clinical treatment, the emergence of chemotherapy resistance seriously affects the effectiveness of treatment. Thus, finding new chemotherapeutic sensitizers is considered to be...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-12-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-022-00601-2 |
| _version_ | 1828115118628536320 |
|---|---|
| author | Jianjun Li Yaqi Kou Xiaohan Zhang Xuechun Xiao Yang Ou Lixia Cao Min Guo Chunchun Qi Zhaoyang Wang Yuxin Liu Qiuying Shuai Hang Wang Shuang Yang |
| author_facet | Jianjun Li Yaqi Kou Xiaohan Zhang Xuechun Xiao Yang Ou Lixia Cao Min Guo Chunchun Qi Zhaoyang Wang Yuxin Liu Qiuying Shuai Hang Wang Shuang Yang |
| author_sort | Jianjun Li |
| collection | DOAJ |
| description | Abstract Lung adenocarcinoma is the major subtype of lung cancer, accounting for approximately 40% of lung cancers. During clinical treatment, the emergence of chemotherapy resistance seriously affects the effectiveness of treatment. Thus, finding new chemotherapeutic sensitizers is considered to be one of the effective solutions. Biochanin A, as a naturally occurring isoflavone, has been demonstrated to exhibit anticancer effects in various tumors. However, the potential mechanisms of Biochanin A to inhibit tumor development have not been clarified. In the present study, we found that the combinational treatment of cisplatin and Biochanin A exhibited strong synergistic repression on lung adenocarcinoma growth and progression in vitro and in vivo. Considering that epithelial–mesenchymal transition (EMT) is recognized to be associated with both chemoresistance and metastasis, we examined the EMT-related markers and found that Biochanin A could specifically inhibit the expression of ZEB1. Importantly, Biochanin A chemosensitizes lung adenocarcinoma and inhibits cancer cell metastasis by suppressing ZEB1. At the molecular level, Biochanin A affects the stability of ZEB1 protein through the deubiquitination pathway and thereby influences the progression of lung adenocarcinoma. In conclusion, our finding elucidates the potential efficacy of Bichanin A as a chemosensitizer and provides new strategy for the chemotherapy of advanced lung adenocarcinoma. |
| first_indexed | 2024-04-11T12:34:49Z |
| format | Article |
| id | doaj.art-bf84ac006c104abca8d2fee64383d60e |
| institution | Directory Open Access Journal |
| issn | 2730-6011 |
| language | English |
| last_indexed | 2024-04-11T12:34:49Z |
| publishDate | 2022-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj.art-bf84ac006c104abca8d2fee64383d60e2022-12-22T04:23:39ZengSpringerDiscover Oncology2730-60112022-12-0113111410.1007/s12672-022-00601-2Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1Jianjun Li0Yaqi Kou1Xiaohan Zhang2Xuechun Xiao3Yang Ou4Lixia Cao5Min Guo6Chunchun Qi7Zhaoyang Wang8Yuxin Liu9Qiuying Shuai10Hang Wang11Shuang Yang12Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityTianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Medical College of Nankai UniversityAbstract Lung adenocarcinoma is the major subtype of lung cancer, accounting for approximately 40% of lung cancers. During clinical treatment, the emergence of chemotherapy resistance seriously affects the effectiveness of treatment. Thus, finding new chemotherapeutic sensitizers is considered to be one of the effective solutions. Biochanin A, as a naturally occurring isoflavone, has been demonstrated to exhibit anticancer effects in various tumors. However, the potential mechanisms of Biochanin A to inhibit tumor development have not been clarified. In the present study, we found that the combinational treatment of cisplatin and Biochanin A exhibited strong synergistic repression on lung adenocarcinoma growth and progression in vitro and in vivo. Considering that epithelial–mesenchymal transition (EMT) is recognized to be associated with both chemoresistance and metastasis, we examined the EMT-related markers and found that Biochanin A could specifically inhibit the expression of ZEB1. Importantly, Biochanin A chemosensitizes lung adenocarcinoma and inhibits cancer cell metastasis by suppressing ZEB1. At the molecular level, Biochanin A affects the stability of ZEB1 protein through the deubiquitination pathway and thereby influences the progression of lung adenocarcinoma. In conclusion, our finding elucidates the potential efficacy of Bichanin A as a chemosensitizer and provides new strategy for the chemotherapy of advanced lung adenocarcinoma.https://doi.org/10.1007/s12672-022-00601-2Lung adenocarcinomaBiochanin AZEB1ChemosensitizationProteasomal ubiquitination |
| spellingShingle | Jianjun Li Yaqi Kou Xiaohan Zhang Xuechun Xiao Yang Ou Lixia Cao Min Guo Chunchun Qi Zhaoyang Wang Yuxin Liu Qiuying Shuai Hang Wang Shuang Yang Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1 Discover Oncology Lung adenocarcinoma Biochanin A ZEB1 Chemosensitization Proteasomal ubiquitination |
| title | Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1 |
| title_full | Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1 |
| title_fullStr | Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1 |
| title_full_unstemmed | Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1 |
| title_short | Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1 |
| title_sort | biochanin a inhibits lung adenocarcinoma progression by targeting zeb1 |
| topic | Lung adenocarcinoma Biochanin A ZEB1 Chemosensitization Proteasomal ubiquitination |
| url | https://doi.org/10.1007/s12672-022-00601-2 |
| work_keys_str_mv | AT jianjunli biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT yaqikou biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT xiaohanzhang biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT xuechunxiao biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT yangou biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT lixiacao biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT minguo biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT chunchunqi biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT zhaoyangwang biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT yuxinliu biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT qiuyingshuai biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT hangwang biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 AT shuangyang biochaninainhibitslungadenocarcinomaprogressionbytargetingzeb1 |